Globus Medical price target lowered to $68 from $80 at Truist

Truist lowered the firm’s price target on Globus Medical (GMED) to $68 from $80 and keeps a Hold rating on the shares. The firm cites the company’s surprising Q1 earnings and revenue miss, noting that while distributor and supply chain items should prove somewhat transitory, the weaker capital sales from elongating robot deals is a bit more concerning, the analyst tells investors in a research note.